Stock RYTM RHYTHM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
43.76 USD +6.78% Intraday chart for Rhythm Pharmaceuticals, Inc. +14.32% -4.81%
04-30 Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology CI
04-18 Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
GL
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
GL
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
GL
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
AQ
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
AQ
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
GL
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
GL
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
AQ
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
AQ
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
AQ
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
GL
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
AQ
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
GL
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
AQ
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RYTM Stock
  4. News Rhythm Pharmaceuticals, Inc.
  5. Press Releases